Acalabrutinib works by selectively inhibiting the BTK enzyme. By blocking this enzyme, the drug disrupts key signaling pathways that are essential for the proliferation and survival of B-cell malignancies. This inhibition leads to the death of cancer cells and a reduction in tumor growth.
